[Skip navigation]FDA Logo links to FDA home page
Center for Drug Evaluation and Research, U.S. Food and Drug AdministrationU.S. Food and Drug AdministrationCenter for Drug Evaluation and Research
 HHS Logo links to Department of Health and Human Services website

FDA Home Page | CDER Home Page | CDER Site Info | Contact CDER | What's New @ CDER

horizonal rule
CDER Home About CDER Drug Information Regulatory Guidance CDER Calendar Specific Audiences CDER Archives
 
Powered by Google
 

 Tositumomab and Iodine I 131 Tositumomab

Product Approval Information - Licensing Action

Proper name: Tositumomab and Iodine I 131 Tositumomab
Tradename: Bexxar
Manufacturer: Corixa Corporation, Seattle, WA, License #1614
Indication for Use: Treatment of patients with CD20 positive, follicular, non-Hodgkin's lymphoma, with and without transformation, whose disease is refractory to Rituximab and has relapsed following chemotherapy
Approval Date: 6/27/2003
Type of submission: Biologics license application

Approval Letter (Text)

Labeling (PDF)

Last Updated: 7/2/2003

 

Back to Top     Back to Index

Updated: September 25, 2003
horizonal rule

CDER Home Page | CDER Site Info | Contact CDER | What's New @ CDER
FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA | HHS Home Page

FDA/Center for Drug Evaluation and Research